Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
Bio-Path Holdings (BPTH) has announced a corporate update conference call and audio webcast scheduled for May 29, 2025, at 8:30 a.m. ET. The company, which specializes in DNAbilize® antisense RNAi nanoparticle technology, will provide a comprehensive business overview during the call.
Bio-Path's pipeline includes several key candidates: prexigebersen (BP1001) in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors and obesity treatment, and BP1002 targeting Bcl-2 protein for blood cancers and solid tumors. Additionally, the company plans to file an IND application for BP1003, a STAT3 inhibitor.
Bio-Path Holdings (BPTH) ha annunciato una conferenza telefonica di aggiornamento aziendale e una trasmissione audio in webcast previste per il 29 maggio 2025 alle 8:30 ET. L'azienda, specializzata nella tecnologia nanoparticellare DNAbilize® antisense RNAi, fornirà una panoramica completa del business durante la chiamata.
Il portafoglio di Bio-Path comprende diversi candidati chiave: prexigebersen (BP1001) in Fase 2 per i tumori del sangue, BP1001-A in Fase 1/1b per tumori solidi e trattamento dell'obesità, e BP1002 che mira alla proteina Bcl-2 per tumori del sangue e solidi. Inoltre, la società prevede di presentare una domanda IND per BP1003, un inibitore di STAT3.
Bio-Path Holdings (BPTH) ha anunciado una conferencia telefónica de actualización corporativa y una transmisión de audio en webcast programadas para el 29 de mayo de 2025 a las 8:30 a.m. ET. La compañía, especializada en la tecnología de nanopartículas de ARN antisentido DNAbilize®, ofrecerá una visión general completa del negocio durante la llamada.
La cartera de Bio-Path incluye varios candidatos clave: prexigebersen (BP1001) en Fase 2 para cánceres de sangre, BP1001-A en Fase 1/1b para tumores sólidos y tratamiento de la obesidad, y BP1002 que apunta a la proteína Bcl-2 para cánceres de sangre y tumores sólidos. Además, la compañía planea presentar una solicitud IND para BP1003, un inhibidor de STAT3.
Bio-Path Holdings (BPTH)는 2025년 5월 29일 오전 8시 30분 ET에 예정된 기업 업데이트 컨퍼런스 콜 및 오디오 웹캐스트를 발표했습니다. DNAbilize® 안티센스 RNAi 나노입자 기술을 전문으로 하는 이 회사는 콜 중에 포괄적인 비즈니스 개요를 제공할 예정입니다.
Bio-Path의 파이프라인에는 주요 후보 물질들이 포함되어 있습니다: 혈액암을 위한 2상(prexigebersen (BP1001)), 고형암 및 비만 치료를 위한 1/1b상(BP1001-A), 혈액암 및 고형암을 표적으로 하는 Bcl-2 단백질 대상(BP1002). 또한 회사는 STAT3 억제제인 BP1003에 대한 IND 신청서를 제출할 계획입니다.
Bio-Path Holdings (BPTH) a annoncé une conférence téléphonique de mise à jour d'entreprise et une diffusion audio en webcast prévues pour le 29 mai 2025 à 8h30 ET. La société, spécialisée dans la technologie nanoparticulaire antisens ARN RNAi DNAbilize®, fournira un aperçu complet de ses activités lors de cet appel.
Le portefeuille de Bio-Path comprend plusieurs candidats clés : prexigebersen (BP1001) en phase 2 pour les cancers du sang, BP1001-A en phase 1/1b pour les tumeurs solides et le traitement de l'obésité, ainsi que BP1002 ciblant la protéine Bcl-2 pour les cancers du sang et les tumeurs solides. De plus, la société prévoit de déposer une demande IND pour BP1003, un inhibiteur de STAT3.
Bio-Path Holdings (BPTH) hat eine Telefonkonferenz zur Unternehmensaktualisierung und eine Audio-Webcast für den 29. Mai 2025 um 8:30 Uhr ET angekündigt. Das Unternehmen, das sich auf die DNAbilize® Antisense RNAi Nanopartikel-Technologie spezialisiert hat, wird während des Anrufs einen umfassenden Geschäftsüberblick geben.
Die Pipeline von Bio-Path umfasst mehrere wichtige Kandidaten: prexigebersen (BP1001) in Phase 2 für Blutkrebs, BP1001-A in Phase 1/1b für solide Tumore und Fettleibigkeitsbehandlung sowie BP1002, das auf das Bcl-2-Protein bei Blutkrebs und soliden Tumoren abzielt. Zusätzlich plant das Unternehmen die Einreichung eines IND-Antrags für BP1003, einen STAT3-Inhibitor.
- None.
- None.
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview.
To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. BP1001-A is also being evaluated as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
When is Bio-Path Holdings (BPTH) hosting its corporate update conference call in May 2025?
What clinical trials is Bio-Path Holdings (BPTH) currently conducting?
How can investors access Bio-Path Holdings' May 2025 conference call?
What is Bio-Path Holdings' main technology platform?
